secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2022-11-22T23:59:59+00:00
Accession:  0001193125-22-290176
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

CytomX and Regeneron enter $30M upfront cancer bi-specific collaboration; up to $2B milestones
--------------------------------------------------------------------------------

- CytomX receives $30M upfront from Regeneron; eligible for up to $2B in development/regulatory milestones.
- Tiered royalties from high single digit to low-teen percentages on global net sales of licensed products.
- Collaboration uses CytomX's Probody platform and Regeneron's Veloci-Bi bispecific platform for conditionally-activated cancer therapies.
- Regeneron fully funds all preclinical, development, manufacturing, and commercialization activities worldwide.
- CytomX grants exclusive worldwide royalty-bearing license to Regeneron for oncology; Regeneron may terminate programs on 30 days' notice after 2 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000119312522290176/0001193125-22-290176-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000119312522290176/d402086d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-290176

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer